Your browser is no longer supported. Please, upgrade your browser.
Settings
EVFM Evofem Biosciences, Inc. daily Stock Chart
EVFM [NASD]
Evofem Biosciences, Inc.
Index- P/E- EPS (ttm)-3.08 Insider Own31.20% Shs Outstand46.40M Perf Week-5.61%
Market Cap218.54M Forward P/E- EPS next Y-1.20 Insider Trans- Shs Float31.95M Perf Month-27.31%
Income-74.70M PEG- EPS next Q-0.37 Inst Own55.70% Short Float0.75% Perf Quarter14.88%
Sales- P/S- EPS this Y-32.50% Inst Trans9.50% Short Ratio1.71 Perf Half Y25.60%
Book/sh-1.07 P/B- EPS next Y23.10% ROA-617.10% Target Price10.40 Perf Year88.40%
Cash/sh0.00 P/C1092.72 EPS next 5Y30.40% ROE524.30% 52W Range1.79 - 7.24 Perf YTD12.41%
Dividend- P/FCF- EPS past 5Y2.80% ROI- 52W High-34.67% Beta0.63
Dividend %- Quick Ratio0.00 Sales past 5Y- Gross Margin- 52W Low163.98% ATR0.49
Employees30 Current Ratio0.00 Sales Q/Q- Oper. Margin- RSI (14)38.08 Volatility5.20% 9.49%
OptionableNo Debt/Eq- EPS Q/Q85.40% Profit Margin- Rel Volume0.19 Prev Close4.71
ShortableYes LT Debt/Eq- EarningsAug 06 BMO Payout- Avg Volume140.51K Price4.73
Recom- SMA20-17.37% SMA50-17.62% SMA20012.79% Volume27,144 Change0.42%
Jul-01-19 09:31AM  Evofem Biosciences Added to Russell 3000® Index PR Newswire -14.91%
Jun-10-19 04:01PM  Evofem Biosciences Closes $80 Million Financing Transaction with PDL BioPharma and Other Long-time Investors PR Newswire
May-30-19 11:02AM  PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts Zacks +8.78%
May-14-19 09:00AM  Evofem Biosciences to Present at 2019 RBC Capital Markets Global Healthcare Conference PR Newswire +6.80%
May-10-19 10:51AM  PDL BioPharma (PDLI) Q1 Earnings Top Mark, Revenues Rise Y/Y Zacks +16.87%
May-09-19 07:24PM  PDL Biopharma Inc (PDLI) Q1 2019 Earnings Call Transcript Motley Fool
May-07-19 06:00AM  Evofem Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update PR Newswire +5.70%
Apr-30-19 09:00AM  Evofem Biosciences to Report First Quarter 2019 Results and Provide Corporate Update on May 7, 2019 PR Newswire
Apr-23-19 08:11AM  Evofem Biosciences Announces Last Patient Enrolled for AMPREVENCE, the Phase 2b Sexually Transmitted Infections Trial of Amphora PR Newswire -6.62%
Apr-16-19 08:30AM  STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Evofem Biosciences, Inc. EVFM GlobeNewswire
Apr-11-19 10:25AM  PDL BioPharma Announces Equity Investment in Evofem Biosciences PR Newswire +14.88%
10:19AM  Evofem Biosciences Enters into Financing Agreement for up to $80 Million, Closes First Tranche of Strategic Investment from PDL BioPharma PR Newswire
06:54AM  Evofem Biosciences raises $80m for new hormone-free contraceptive Financial Times
Apr-03-19 09:00AM  Evofem Biosciences to Present at Needham Healthcare Conference PR Newswire
Mar-12-19 09:00AM  Evofem Biosciences to Present at Upcoming Investor Conferences PR Newswire
Mar-03-19 11:00PM  Edited Transcript of EVFM earnings conference call or presentation 1-Mar-19 4:00pm GMT Thomson Reuters StreetEvents
Mar-01-19 06:00AM  Evofem Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update PR Newswire -12.05%
Feb-19-19 09:00AM  Evofem Biosciences to Report Fourth Quarter and Year-end 2018 Results and Provide Corporate Update on March 1, 2019 PR Newswire
Jan-07-19 07:20AM  Evofem Biosciences, Amphora a Potential New Birth Control, Analysts Review and Target ACCESSWIRE
Jan-03-19 08:00AM  Evofem Biosciences Provides Corporate Update and Announces Upcoming Milestones PR Newswire -5.66%
07:06AM  Edited Transcript of EVFM earnings conference call or presentation 7-Nov-18 4:00pm GMT Thomson Reuters StreetEvents
Dec-20-18 10:13AM  The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte Zacks
Dec-19-18 09:17AM  Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY Zacks
Dec-18-18 02:01PM  Evofem Shares Up as Birth Control Gel Succeeds in Phase III Zacks -15.80%
06:55AM  Today's Research Reports on Trending Tickers: Evofem Biosciences and Diffusion Pharmaceuticals ACCESSWIRE
Dec-17-18 01:30PM  4 Stocks Providing Investor Opportunity Right Now ACCESSWIRE +14.42%
06:22AM  Evofem's hormone-free birth control gel meets main goal in key study Reuters
06:00AM  Evofem Biosciences Announces Positive Top-Line Results of Phase 3 Study Evaluating Amphora for Hormone-Free Birth Control PR Newswire
Nov-15-18 06:50AM  Evofem Biosciences to Present at Piper Jaffray Healthcare Conference on November 27, 2018 PR Newswire
Nov-08-18 06:50AM  Evofem Biosciences Completes Phase 3 Clinical Trial of Amphora for Prevention of Pregnancy PR Newswire
Nov-07-18 06:50AM  Evofem Biosciences Reports Third Quarter 2018 Financial Results and Provides Corporate Update PR Newswire -8.25%
Nov-01-18 08:00AM  Evofem Biosciences to Host Key Opinion Leader Event: New Perspectives in Birth Control--Non-Hormonal, On Demand and Woman Controlled PR Newswire +7.16%
Oct-24-18 08:30AM  Evofem Biosciences to Report Third Quarter 2018 Results on November 7, 2018 PR Newswire -7.14%
Oct-09-18 02:21PM  Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Lead Product Candidate, Amphora, and its Role as a Multipurpose Vaginal pH Regulator Presented at 2018 American Society of Reproductive Medicine Annual Congress PR Newswire
Sep-26-18 08:00AM  Survey Reveals High Number of Sexually Active Women Who Use No Birth Control Method, Supporting the Continued Need for Non-Hormonal Birth Control Innovations such as Evofem Biosciences' Product Candidate Amphora® PR Newswire +9.88%
Sep-21-18 08:00AM  New Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Amphora and its Role as a Multipurpose Vaginal pH Regulator (MVP-R) to be Presented at the 2018 American Society For Reproductive Medicine (ASRM) Annual Congress PR Newswire
Sep-18-18 08:00AM  Evofem Biosciences to Present at Upcoming Investor Conferences PR Newswire
Sep-11-18 10:24AM  3 Small Biotech Stocks That Almost Doubled in Past Month Zacks -14.50%
Aug-29-18 09:00AM  Rise in Prevalence of STDs Reported by CDC Supports Continued Development of Novel Solutions, Like Evofem's Product in Development, Amphora®, for the Prevention of Chlamydia PR Newswire +20.27%
Aug-23-18 09:00AM  Evofem Biosciences to Present at 20th Annual Global Investment Conference on September 6, 2018 PR Newswire
Aug-07-18 09:00AM  Evofem Biosciences' Chief Medical Officer, Dr. Kelly Culwell, to Present at #BlogHer18 Creators Summit PR Newswire -6.10%
Aug-02-18 06:50AM  Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update PR Newswire -8.29%
Jul-19-18 08:30AM  Evofem Biosciences to Report Second Quarter 2018 Results and Provide Corporate Update on August 2, 2018 PR Newswire
Jun-07-18 07:38PM  Should You Be Concerned About Evofem Biosciences Incs (NASDAQ:EVFM) Shareholders? Simply Wall St.
May-29-18 12:00PM  Evofem Biosciences to Present at Jefferies Global Healthcare Conference on June 7, 2018 PR Newswire -5.81%
May-24-18 04:01PM  Evofem Biosciences Announces Closing of Public Offering of Common Stock and Warrants PR Newswire
May-22-18 09:00AM  Evofem Biosciences Announces Pricing of Public Offering of Common Stock and Warrants PR Newswire -12.95%
Apr-24-18 06:50AM  Evofem Biosciences Announces Proposed Public Offering of Common Stock PR Newswire
Feb-21-18 06:55AM  Evofem Biosciences Receives Fast Track Designation for Amphora for Prevention of Chlamydia PR Newswire
Feb-16-18 06:55AM  Evofem Biosciences to Present at RBC Global Healthcare Conference PR Newswire
Feb-15-18 06:55AM  Evofem Biosciences Completes Enrollment of Phase 3 Contraceptive Trial of Amphora Ahead of Schedule PR Newswire
Jan-30-18 02:31PM  Evofem Biosciences Inc (NASDAQ:EVFM): Is Healthcare Attractive Relative To NasdaqCM Peers? Simply Wall St.
Jan-23-18 07:30AM  Evofem Biosciences Announces First Patient Enrolled in Phase 2b/3 STI Trial of Amphora® and Expects Phase 3 Contraceptive Clinical Trial Data First Quarter 2019 PR Newswire
Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of chlamydia and gonorrhea in women. The company is also developing multi-purpose vaginal pH regulator gel product candidate for the reduction of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.